| Cat. No. |
Product |
Quantity/Size |
Price |
Data |
|
| CPC538B |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike Glycoprotein Sotrovimab (VIR-7831 / GSK4182136) Neutralizing mAb |
100 µg |
Please Inquire |
 |
BUY
|
| CPC538A |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike Glycoprotein Sotrovimab (VIR-7831 / GSK4182136) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC537B |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC537A |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC523A |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC522A |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC523B |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC522B |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC521A |
Human Anti-SARS-CoV-2 Spike RBD (H4) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC521B |
Human Anti-SARS-CoV-2 Spike RBD (H4) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC520B |
Human Anti-SARS-CoV-2 Spike S1 (CR3022) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC520A |
Human Anti-SARS-CoV-2 Spike S1 (CR3022) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC542C |
Human Anti-SARS-CoV-2 Spike-RBD (002-S21F2) Broad-Neutralizing mAb |
1.0 mg |
Please Inquire |
|
BUY
|
| CPC513B |
Human Anti-SARS-CoV-2 Spike-RBD (EY6A) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC513A |
Human Anti-SARS-CoV-2 Spike-RBD (EY6A) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC539C |
Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb |
1.0 mg |
Please Inquire |
|
BUY
|
| CPC539A |
Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC539B |
Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC516B |
Human Anti-SARS-CoV-2 Spike-RBD Etesevimab (CB6, JS016, LY-CoV-016) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC516A |
Human Anti-SARS-CoV-2 Spike-RBD Etesevimab (CB6, JS016, LY-CoV-016) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC541B |
Human Anti-SARS-CoV-2 Spike-RBD Neutralizing (S2E12) mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC541C |
Human Anti-SARS-CoV-2 Spike-RBD Neutralizing (S2E12) mAb |
1.0 mg |
Please Inquire |
|
BUY
|
| CPC541A |
Human Anti-SARS-CoV-2 Spike-RBD Neutralizing (S2E12) mAb |
50 µg |
Please Inquire |
|
BUY
|
| DHE16603B |
Research Grade Alacizumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHE16603A |
Research Grade Alacizumab |
100 ug |
$380.00
|
|
BUY
|
| DHG52001B |
Research Grade Anetumab
|
1.0 mg |
$1,520.00
|
|
BUY
|
| DHG52001A |
Research Grade Anetumab
|
100 ug |
$420.00
|
|
BUY
|
| DHD34004B |
Research Grade Anti-Human CD120a/TNFRSF1A/TNFR1 (GSK2862277) |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHD34004A |
Research Grade Anti-Human CD120a/TNFRSF1A/TNFR1 (GSK2862277) |
100 µg |
$380.00
|
|
BUY
|
| DHF68802A |
Research Grade Anti-Human CD156b/ADAM17 (D8P1C1) |
100 ug |
$475.00
|
|
BUY
|
| DHF68802B |
Research Grade Anti-Human CD156b/ADAM17 (D8P1C1) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHF68801B |
Research Grade Anti-Human CD156b/ADAM17 (MEDI3622) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHF68801A |
Research Grade Anti-Human CD156b/ADAM17 (MEDI3622) |
100 ug |
$475.00
|
|
BUY
|
| DHJ14403B |
Research Grade Anti-Human CD272/BTLA (ANB032) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHJ14403A |
Research Grade Anti-Human CD272/BTLA (ANB032) |
100 µg |
$475.00
|
|
BUY
|
| DHE25604A |
Research Grade Anti-Human CD66c/CEACAM6 (NOV1803) mAb |
100 ug |
$640.00
|
|
BUY
|
| DHE25604B |
Research Grade Anti-Human CD66c/CEACAM6 (NOV1803) mAb |
1.0 mg |
$2,410.00
|
|
BUY
|
| DHD48801B |
Research Grade Anti-Human CD9 (AT14-012) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHD48801A |
Research Grade Anti-Human CD9 (AT14-012) |
100 ug |
$475.00
|
|
BUY
|
| DHJ05001A |
Research Grade Anti-Human IL31 (BMS-981164) |
100 ug |
$475.00
|
|
BUY
|
| DHJ05001B |
Research Grade Anti-Human IL31 (BMS-981164) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHD00501A |
Research Grade Anti-Human OSM/Oncostatin-M (GSK2330811) |
100 ug |
$475.00
|
|
BUY
|
| DHD00501B |
Research Grade Anti-Human OSM/Oncostatin-M (GSK2330811) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHD00502A |
Research Grade Anti-Human OSM/Oncostatin-M (GSK315234) |
100 ug |
$475.00
|
|
BUY
|
| DHD00502B |
Research Grade Anti-Human OSM/Oncostatin-M (GSK315234) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHK13704A |
Research Grade Anti-Human SIGLEC15/CD33L3 (DS1501) mAb |
100 µg |
$420.00
|
|
BUY
|
| DHK13704B |
Research Grade Anti-Human SIGLEC15/CD33L3 (DS1501) mAb |
1.0 mg |
$1,520.00
|
|
BUY
|
| DHE22008B |
Research Grade Anti-Human SNCA/Alpha-synuclein (Lu AF82422) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHE22008A |
Research Grade Anti-Human SNCA/Alpha-synuclein (Lu AF82422) |
100 ug |
$475.00
|
|
BUY
|
| DHH72415A |
Research Grade Anti-Human TIGIT (BMS 986207) |
100 ug |
$420.00
|
|
BUY
|
| DHH72415B |
Research Grade Anti-Human TIGIT (BMS 986207) |
1.0 mg |
$1,520.00
|
|
BUY
|
| DHH72416A |
Research Grade Anti-Human TIGIT (COM902) |
100 ug |
$420.00
|
|
BUY
|
| DHH72416B |
Research Grade Anti-Human TIGIT (COM902) |
1.0 mg |
$1,520.00
|
|
BUY
|
| DHK23201A |
Research Grade Anti-Human TNFRSF25 (PTX-35) mAb |
100 µg |
$475.00
|
|
BUY
|
| DHK23201B |
Research Grade Anti-Human TNFRSF25 (PTX-35) mAb |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHB54003A |
Research Grade Anti-Human TNFSF15/TL1A (PRA023) |
100 µg |
$405.00
|
|
BUY
|
| DHB54003B |
Research Grade Anti-Human TNFSF15/TL1A (PRA023) |
1.0 mg |
$1,520.00
|
|
BUY
|
| DHG62603B |
Research Grade Anti-Human TPBG/5T4 (ASN004) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHG62603A |
Research Grade Anti-Human TPBG/5T4 (ASN004) |
100 ug |
$475.00
|
|
BUY
|
| DVV00332B |
Research Grade Anti-SARS-CoV-2 Spike Protein/RBD Broad-Neutralizing Antibody (002-S21F2) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DVV00332A |
Research Grade Anti-SARS-CoV-2 Spike Protein/RBD Broad-Neutralizing Antibody (002-S21F2) |
100 µg |
$475.00
|
|
BUY
|
| DVV00317A |
Research Grade Anti-SARS-CoV-2 Spike-RBD (S2H97) mAb |
100 µg |
$420.00
|
|
BUY
|
| DVV00317B |
Research Grade Anti-SARS-CoV-2 Spike-RBD (S2H97) mAb |
1.0 mg |
$1,520.00
|
|
BUY
|
| DVV00317B-BT |
Research Grade Anti-SARS-CoV-2 Spike-RBD (S2H97) mAb, Biotin labeled |
1.0 mg |
$2,310.00
|
|
BUY
|
| DVV00317X-BT |
Research Grade Anti-SARS-CoV-2 Spike-RBD (S2H97) mAb, Biotin labeled |
0.5 mg |
$1,485.00
|
|
BUY
|
| DHD47902B |
Research Grade Aprutumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHD47902A |
Research Grade Aprutumab |
100 ug |
$380.00
|
|
BUY
|
| DHJ64002B |
Research Grade Azintuxizumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHJ64002A |
Research Grade Azintuxizumab |
100 ug |
$380.00
|
|
BUY
|
| DHH02203A |
Research Grade Balstilimab |
100 ug |
$380.00
|
|
BUY
|
| DHH02203B |
Research Grade Balstilimab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHD47901B |
Research Grade Bemarituzumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHD47901A |
Research Grade Bemarituzumab |
100 ug |
$380.00
|
|
BUY
|
| DHH02210A |
Research Grade Budigalimab |
100 ug |
$380.00
|
|
BUY
|
| DHH02210B |
Research Grade Budigalimab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHH02211A |
Research Grade Camrelizumab |
100 ug |
$380.00
|
|
BUY
|
| DHH02211B |
Research Grade Camrelizumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHH02204A |
Research Grade Cetrelimab |
100 ug |
$380.00
|
|
BUY
|
| DHH02204B |
Research Grade Cetrelimab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHD17401A |
Research Grade Citatuzumab |
100 ug |
$380.00
|
|
BUY
|
| DHD17401B |
Research Grade Citatuzumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHC09603A |
Research Grade Disitamab |
100 ug |
$380.00
|
|
BUY
|
| DHC09603B |
Research Grade Disitamab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DVV00306A |
Research Grade Etesevimab |
100 ug |
$475.00
|
|
BUY
|
| DVV00306B |
Research Grade Etesevimab |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHH02220A |
Research Grade Ezabenlimab |
100 ug |
$380.00
|
|
BUY
|
| DHH02220B |
Research Grade Ezabenlimab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHJ92102A |
Research Grade Feladilimab |
100 ug |
$380.00
|
|
BUY
|
| DHJ92102B |
Research Grade Feladilimab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHC09606A |
Research Grade Gancotamab |
100 ug |
$490.00
|
|
BUY
|
| DHC09606B |
Research Grade Gancotamab |
1.0 mg |
$1,790.00
|
|
BUY
|
| DHH02212A |
Research Grade Lodapolimab |
100 ug |
$380.00
|
|
BUY
|
| DHH02212B |
Research Grade Lodapolimab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHE16602A |
Research Grade Olinvacimab |
100 ug |
$430.00
|
|
BUY
|
| DHE16602B |
Research Grade Olinvacimab |
1.0 mg |
$1,560.00
|
|
BUY
|
| DHD17405A |
Research Grade Oportuzumab |
100 ug |
$490.00
|
|
BUY
|
| DHD17405B |
Research Grade Oportuzumab |
1.0 mg |
$1,790.00
|
|
BUY
|
| DHH02216A |
Research Grade Pidilizumab |
100 ug |
$380.00
|
|
BUY
|
| DHH02216B |
Research Grade Pidilizumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHJ48301A |
Research Grade Ponsegromab |
100 ug |
$420.00
|
|
BUY
|
